株式会社PRISM BioLab Logo

株式会社PRISM BioLab

A biotech creating novel drugs by targeting previously "undruggable" protein interactions.

206A | T

Overview

Corporate Details

ISIN(s):
JP3833190006
LEI:
Country:
Japan
Address:
藤沢市村岡東二丁目26番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

PRISM BioLab is a biotechnology company dedicated to creating novel small molecule drugs for diseases that currently lack effective treatments. The company's core is its proprietary PepMetics® drug discovery platform, which enables the targeting of previously "undruggable" proteins. This technology utilizes unique small molecule scaffolds that mimic peptide structures (α-helices and β-turns) to control protein-protein interactions (PPIs), a key cause of many diseases. By making these challenging targets accessible, PRISM BioLab aims to pioneer new therapies and collaborates with pharmaceutical companies to advance its drug discovery programs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-17 09:30
Major Shareholding Notification
臨時報告書
Japanese 21.0 KB
2025-05-14 09:31
Registration Form
確認書
Japanese 8.7 KB
2025-05-14 09:30
Interim Report
半期報告書-第14期(2024/10/01-2025/09/30)
Japanese 224.7 KB
2024-12-27 07:34
Governance Information
内部統制報告書-第13期(2023/10/01-2024/09/30)
Japanese 22.2 KB
2024-12-27 07:33
Registration Form
確認書
Japanese 8.7 KB
2024-12-27 07:32
Registration Form
有価証券報告書-第13期(2023/10/01-2024/09/30)
Japanese 3.1 MB
2024-12-27 07:31
Post-Annual General Meeting Information
臨時報告書
Japanese 22.1 KB
2024-11-14 07:32
Regulatory News Service
臨時報告書
Japanese 20.8 KB
2024-10-16 10:12
Major Shareholding Notification
臨時報告書
Japanese 20.7 KB
2024-09-10 09:09
Regulatory News Service
臨時報告書
Japanese 19.9 KB
2024-06-24 08:00
Prospectus
訂正有価証券届出書(新規公開時)
Japanese 2.2 MB
2024-06-14 08:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.3 MB
2024-05-27 08:00
Registration Form
有価証券届出書(新規公開時)
Japanese 4.3 MB

Automate Your Workflow. Get a real-time feed of all 株式会社PRISM BioLab filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for 株式会社PRISM BioLab

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for 株式会社PRISM BioLab via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Vivoryon Therapeutics N.V. Logo
Developing first-in-class small molecule therapies for age-related and kidney diseases.
Germany
VVY
VivoSim Labs, INC. Logo
Offers 3D human tissue models for predictive toxicology testing to accelerate drug discovery.
United States of America
VIVS
Develops innovative, non-narcotic drugs for pain and central nervous system (CNS) diseases.
South Korea
082800
VOLITIONRX LTD Logo
Develops epigenetic blood tests for early cancer and sepsis detection in human/veterinary markets.
United States of America
VNRX
vTv Therapeutics Inc. Logo
Develops oral small molecule drugs for type 1 diabetes and other chronic conditions.
United States of America
VTVT
VYNE Therapeutics Inc. Logo
Clinical-stage biopharma developing novel therapies for immuno-inflammatory diseases.
United States of America
VYNE
WAKAMOTO PHARMACEUTICAL CO.,LTD. Logo
Develops gastrointestinal and ophthalmic drugs for the health challenges of an aging society.
Japan
4512
Wave Life Sciences Ltd. Logo
Developing RNA-based medicines for severe genetic diseases like DMD and Huntington's disease.
United States of America
WVE
WELLBIOTEC CO.,LTD Logo
Diversified in biopharma, EV chargers, and lithium supply for batteries.
South Korea
010600
Werewolf Therapeutics, Inc. Logo
Developing tumor-activated immunotherapies for a localized immune attack on cancer.
United States of America
HOWL

Talk to a Data Expert

Have a question? We'll get back to you promptly.